Badanie nad empagliflozyną w zapobieganiu kardiotoksyczności u pacjentów z rakiem poddawanych chemioterapii antracyklinowej

In this study, the focus is on preventing heart damage, known as cardiotoxicity, in patients with cancer who are receiving a type of chemotherapy called anthracyclines. Anthracyclines, such as doxorubicin and epirubicin, are effective cancer treatments but can sometimes harm the heart. The study will test a medication called empagliflozin, which is usually used to treat diabetes, to see if it can protect the heart during chemotherapy. Participants will either receive empagliflozin or a placebo, which looks like the medication but has no active ingredients.

The main goal of the study is to see if empagliflozin can prevent problems with the heart's ability to pump blood, known as left ventricular dysfunction, in patients receiving high doses of anthracyclines. The study will involve patients who have cancer but do not have a history of heart failure. Participants will be randomly assigned to receive either empagliflozin or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is called a double-blind study.

The study will last for a period of time during which participants will be monitored for any changes in their heart function and overall health. The researchers will look at how well the heart is working and check for any side effects from the treatment. The study aims to provide important information on whether empagliflozin can be a safe and effective way to protect the heart in cancer patients undergoing chemotherapy with anthracyclines.